Alerts will be sent to your verified email
Verify Email
LAURUSLABS
|
Laurus Labs
|
Neuland Laboratories
|
Alivus Life Sciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in Canada
|
23.0 | n/a | n/a |
|
Number of ANDA's Filed in Europe
|
21.0 | n/a | n/a |
|
Number of ANDA's Approved in Europe
|
17.0 | n/a | n/a |
|
Number of ANDA's Filed in USA
|
43.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
35.0 . | n/a | n/a |
|
Number of ANDA's Approved by Canada
|
16.0 | n/a | n/a |
|
US DMF Filings
|
90.0 . | 72.0 . | 561.0 . |
|
R&D as a % of Total Sales
|
4.6 % | 2.79 % | 3.4 % |
|
Financials
|
|||
|
5 yr Average ROE
|
18.77 % | 11.99 % | 37.41 % |
|
5yr average Equity Multiplier
|
2.06 | 1.62 | 2.33 |
|
5yr Average Asset Turnover Ratio
|
0.71 | 0.72 | 0.76 |
|
5yr Avg Net Profit Margin
|
11.95 % | 10.09 % | 20.19 % |
|
Price to Book
|
8.47 | 10.2 | 4.36 |
|
P/E
|
105.68 | 59.78 | 25.28 |
|
5yr Avg Cash Conversion Cycle
|
91.73 Days | 45.08 Days | 76.63 Days |
|
Inventory Days
|
114.71 Days | 89.03 Days | 93.94 Days |
|
Days Receivable
|
120.6 Days | 86.1 Days | 125.3 Days |
|
Days Payable
|
145.16 Days | 113.14 Days | 114.87 Days |
|
5yr Average Interest Coverage Ratio
|
8.98 | 12.92 | 320.13 |
|
5yr Avg ROCE
|
22.73 % | 16.09 % | 51.63 % |
|
5yr Avg Operating Profit Margin
|
24.36 % | 19.31 % | 30.06 % |
|
5 yr average Debt to Equity
|
0.56 | 0.21 | 0.0 |
|
5yr CAGR Net Profit
|
-18.29 % | 79.26 % | 8.5 % |
|
5yr Average Return on Assets
|
8.99 % | 7.75 % | 15.32 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
27.62 % | 32.68 % | 74.99 % |
|
Share Pledged by Promoters
|
2.69 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.35 % | -3.54 % | -7.86 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
3.37 % | 6.64 % | 3.09 % |